IL0011326795

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial ResultsPolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

June 16, 2025 19:20 ET  | Source: PolyPid Ltd. The Company Anticipates that with this Additional Funding, PolyPid’s Runway would…

1 month ago
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

June 06, 2025 16:05 ET  | Source: PolyPid Ltd. PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD),…

1 month ago